Biogen (BIIB) Share-based Compensation Growth (5y) (2014 - 2026)
Biogen (BIIB) Share-based Compensation Growth (5y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.43% |
| Mar 31, 2026 | 3.71% |
| Dec 31, 2025 | 3.99% |
| Sep 30, 2025 | 17.58% |
| Jun 30, 2025 | 9.26% |
| Mar 31, 2025 | 3.65% |
| Dec 31, 2024 | 14.36% |
| Sep 30, 2024 | 9.63% |
| Jun 30, 2024 | 6.18% |
| Mar 31, 2024 | 9.76% |
| Dec 31, 2023 | 7.36% |
| Sep 30, 2023 | 10.77% |
| Jun 30, 2023 | 13.30% |
| Mar 31, 2023 | 11.74% |
| Dec 31, 2022 | 17.04% |
| Sep 30, 2022 | 16.14% |
| Jun 30, 2022 | 12.95% |
| Mar 31, 2022 | 12.81% |
| Dec 31, 2021 | 9.71% |
| Sep 30, 2021 | 10.57% |